Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC)

被引：0

作者：

Yang, James Chih-Hsin ^{[1
]}

Ou, Sai-Hong ^{[2
]}

De Petris, Luigi ^{[3
]}

Gadgeel, Shirish ^{[4
]}

Gandhi, Leena ^{[5
]}

Kim, Dong-Wan ^{[6
]}

Barlesi, Fabrice ^{[7
]}

Govindan, Ramaswamy ^{[8
]}

Dingemans, Anne-Marie ^{[9
]}

Crino, Lucio ^{[10
]}

Lena, Herve ^{[11
]}

Popat, Sanjay ^{[12
]}

Ahn, Jin Seok ^{[13
]}

Dansin, Eric ^{[14
]}

Golding, Sophie ^{[15
]}

Bordogna, Walter ^{[15
]}

Balas, Bogdana ^{[15
]}

Morcos, Peter N. ^{[16
]}

Zeaiter, Ali ^{[15
]}

Shaw, Alice ^{[17
]}

机构：

[1] Natl Taiwan Univ, Grad Inst Oncol, Taipei, Taiwan

[2] Univ Calif Irvine, Sch Med, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA

[3] Karolinska Univ Hosp, Oncol, Stockholm, Sweden

[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Seoul Natl Univ Hosp, Seoul, South Korea

[7] Aix Marseille Univ, AP HM, Marseille, France

[8] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA

[9] Maastricht Univ, Med Ctr, Pulm Dis, Maastricht, Netherlands

[10] Perugia Univ Hosp, Perugia, Italy

[11] CHU Rennes, Rennes, France

[12] Imperial Coll London, Royal Marsden Hosp, London, England

[13] Samsung Med Ctr, Seoul, South Korea

[14] Clcc Oscar Lambret, Lille, France

[15] F Hoffmann La Roche Ltd, Basel, Switzerland

[16] Roche, New York, NY USA

[17] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

NSCLC; ALK-inhibitor; Alectinib; phase II pooled analysis;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-016

引用

页码：S1170 / S1171

页数：2